Medical device biocompatibility: where to begin biological safety testing
This article was originally published in RAJ Devices
Nancy J Stark and Daniel E McLain explain why US companies need to reverse their thinking and carry out chemical characterisation of a material before using "the matrix" to look at tissue contact and duration.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.